(E)-4-(5-Hydr­oxy-2-methyl­benzyl­idene­amino)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one

The title compound, C19H19N3O2, is a Schiff base compound derived from 4-amino­anti­pyrine and 5-hydr­oxy-2-methyl­benzaldehyde. The mol­ecule adopts a trans configuration about the central C=N bond. There is an intra­molecular O—H⋯N hydrogen bond. Futhermore, weak C—H⋯O hydrogen bonds lead to the formation of a chain developing parallel to the b axis

(E)-4-(4-Hydr­oxy-3-nitro­benzyl­idene­amino)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one

In the title compound, C18H16N4O4, the dihedral angles between the central pyrazole ring and the pendant substituted and unsubstituted aromatic rings are 4.73 (12) and 44.24 (14)°, respectively. An intra­molecular O—H⋯O hydrogen bond occurs. In the crystal structure, an inter­molecular C—H⋯O inter­action may help to consolidate the packing and a short intra­molecular C—H⋯O contact also occurs

7H-Chromeno[3,2-h]quinolin-7-one methanol monosolvate

The four-ring system in the title compound, C16H9NO2·CH3OH, is planar (r.m.s deviation = 0.03 Å); the methanol solvent mol­ecule forms a hydrogen bond to the quinoline N atom

3-(4-Chloro­phen­yl)-2-(diisopropyl­amino)-1-benzofuro[3,2-d]pyrimidin-4(3H)-one

In the mol­ecule of the title compound, C22H22ClN3O2, the three fused rings of the benzofuro[3,2-d]pyrimidine system are almost coplanar. This ring system is oriented with respect to the substituted benzene ring at a dihedral angle of 79.05 (3)°. Intra­molecular C—H⋯N hydrogen bonding results in the formation of a six-membered ring. In the crystal structure, π–π stacking inter­actions involving the furan, pyrimidinone and benzene rings are present [centroid-to-centroid distances in the range 3.258 (1)–3.870 (1) Å]

acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study

Background There is an unmet need for non-invasive biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) in non-specialized settings. We aimed to develop and validate a non-invasive test for diagnosing NASH in individuals with biopsy-proven nonalcoholic fatty liver disease (NAFLD). Methods We developed a non-invasive test named the acNASH index that combines serum creatinine and aspartate aminotransferase levels in a derivation cohort of 390 Chinese NAFLD patients admitted to the hepatology center of the First Affiliated Hospital of Wenzhou Medical University (China) between December 2016 and September 2019 and subsequently validated in five external cohorts of different ethnicities of patients with biopsy-confirmed NAFLD (pooled n=1,089). Findings The performance of the acNASH index for identifying NASH (defined as NAFLD activity score ≥5 with score of ≥1 for each steatosis, lobular inflammation and ballooning) was good in the derivation cohort with an area under receiver operating characteristics (AUROC) of 0·818 (95%CI 0·777-0·860). A cutoff of acNASH index 7·73 gave a Sp of 91%, Se of 53% and a positive predictive value (PPV) of 85% for ruling-in NASH. In the pooled validation cohort (n=1,089), the diagnostic performance of the index was also good with AUROC=0·805 (95%CI 0·780-0·830), NPV of 93% for ruling-out NASH and PPV of 73% for ruling-in NASH. Subgroup analyses showed similar performance in patients with diabetes or subjects with normal serum transaminase levels. Interpretation The acNASH index shows promising utility as a simple non-invasive biomarker for diagnosing NASH among adults with biopsy-proven NAFLD of different ethnicities from different countries. Funding The National Natural Science Foundation of China (82070588), High Level Creative Talents from Department of Public Health in Zhejiang Province (S2032102600032) and Project of New Century 551 Talent Nurturing in Wenzhou